|
|
Excelsyn sustains strong growth trend28 January 2009 Pharma and biotech services group Excelsyn (Informex Booth 1334) has reported better-than-forecast sales and earnings for the first half of its 2008/09 financial year. Sales from its UK-based Molecular Development business in the six months to 30 November were US $10.98m. , with an EBITDA of US $1.83m. President and CEO Ian Shott commented: “With solid progress in our December – February third quarter, we are on track to more than double our EBITDA for FY 2008-09 – moving up to 16% from the 7% delivered in FY 2007/08”. Excelsyn was also ahead-of-budget for calendar 2008, with sales of US $24.06m., and an EBITDA of US $3.03m. “We have delivered a third year of impressive growth from the pharma services business and are well placed to benefit from the sector’s increasing focus on outsourcing as a key strategy in challenging business conditions”, Shott said. With major synthesis facilities in Holywell, North Wales, Excelsyn specialises in R&D and small scale manufacturing for pharmaceutical and specialty intermediates and APIs. Excelsyn says it has continued to benefit from continuing growth in the outsourcing of both development and manufacturing services by major players in the global pharma and biotech sectors. Business Development VP Mark Chadwick added: “Testing market conditions are favouring proven supplier partners. We continue to build on high levels of repeat business, based on our breadth and track record in key technologies and customer responsiveness.” Excelsyn offers full custom synthesis services throughout the clinical trial pipeline from lead identification to launch; small volume commercial scale API production and complex chemistries at multi hundred kilo scale. Capabilities at the Holywell, North Wales facility have been strengthened over recent months with addition of Fauske adiabetic and TSU calorimetry equipment – enabling the company to conduct stability testing in-house. It has also added laboratory hydrogenation capability with a bench scale 120 bar autoclave and a 3-litre, 5 bar autoclave. Excelsyn has also completed the initial phase of a three-year expansion and upgrade programme at Holywell. Under the new site masterplan, major enhancements will include a new API finishing suite, reactor train alignment and increased product isolation capacity. ________________________________________________ Roger Johnstone |
|||
